Dr Reddys Laboratories Ltd

Dr Reddy's Labs | 500124

Live

₹1,244.40

+₹0.00 (+-0.13%)

As on 18/11/25, 8:52 PM

Market Cap1,03,992.87 CR

Current Price₹1,244.4

High / Low₹1,405.9 / 1,020

PE Ratio16.87

Book Value₹402.27

Dividend Yield0.70%

ROCE23.05%

ROE20.15%

Face Value₹2.00

Current Vol.14,23,044

Average Vol.12,76,53,456

ISININE089A01031

PB Ratio2.84

Debt to Equity0.11

Net Profit Margin17.54

Operating Margin29.61

Stock cgart

Stock Performance

₹2,480₹2,490

₹2,500

Previous CloseToday's Open

₹1,800₹3,000

₹2,500

52W Low52W High

₹2,480Today's Open

₹2,490Previous Close

12,00,000Volume

₹1,80052W Low

₹3,00052W High

Ratios

No data available

About Company

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr
Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology
Reddy's operates in markets across the globe
Its major markets include - USA, India, Russia & CIS countries, and Europe
Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad
The company was established by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh
It was founded to enable patients to access life-saving medicines and to use science and innovations to
open new avenues to meet unmet medical needs

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

;

Technical Indicators

RSI52.18

SMA 201239.29

SMA 501258.83

SMA 1001261.77

SMA 2001230.85

SMA 101217.17

MACD_12_26_Days-7.98

EMA10Day1229.65

EMA20Day1234.29

EMA50Day1247.58

MACD_12_26_9_Days3.53

EMA100Day1252.07

EMA200Day1249.78

Pivot Points

Volume Analysis

Growth Rate

Revenue Growth16.54%

ROE18.53%

EBITDA Margin29.61%

All figures in ₹ Crores

Indicators	2025	2024	2023	2022	2021
Revenue	32,643.90	28,011.10	24,669.70	21,545.20	19,047.50
Interest	282.90	171.10	142.80	95.80	97.00
Expenses	24,096.80	20,078.00	18,320.70	17,777.50	15,177.60
Financing Profit	9,666.10	8,842.10	7,441.50	4,322.40	4,209.30
Financing Margin %	30%	32%	30%	20%	22%
Other Income	1,119.00	909.00	1,092.50	554.70	339.40
Depreciation	1,703.70	1,470.00	1,250.20	1,165.20	1,228.80
Profit before tax	7,679.50	7,201.00	6,048.50	3,061.40	2,883.50
Tax %	25%	23%	25%	29%	32%
Net Profit	5,725.20	5,577.90	4,507.30	2,182.50	1,951.60
EPS in Rs	67.89	67.04	271.47	131.57	117.67

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

Deal	Date	Type	Quantity	Price	Traded %
KAPITALFORENINGEN INVESTIN PRO	09 Sept ‘25	Purchase	5,81,268	₹1,250.6	35.36%
KAPITALFORENINGEN PENSAM INVEST	09 Sept ‘25	Sell	5,81,268	₹1,250.6	35.36%
THE MTBJ LTD. AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849	14 Jul ‘25	Purchase	1,41,606	₹1,254	13.67%
THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828	14 Jul ‘25	Sell	1,41,606	₹1,254	13.67%
ISHARES CORE MSCI EMERGING MARKETS ETF	14 Nov ‘22	Purchase	1,80,717	₹4,539.45	24.27%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	14 Nov ‘22	Sell	1,80,717	₹4,539.45	24.27%
ISHARES CORE MSCI EMERGING MARKETS ETF	03 Nov ‘22	Purchase	1,80,718	₹4,555.65	51.16%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	03 Nov ‘22	Sell	1,80,718	₹4,555.65	51.16%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	03 Oct ‘22	Sell	1,49,492	₹4,335.7	21.50%
ISHARES CORE MSCI EMERGING MARKETS ETF	03 Oct ‘22	Purchase	1,49,492	₹4,335.7	21.50%

News

17 Nov 2025 12:00 am

Dr Reddys Laboratories Ltd up for fifth session

13 Nov 2025 12:00 am

Dr Reddys Laboratories allots 7,430 equity shares under ESOS

Record Date

Corporate Action

Information

Announcement Day

24 Jul 2025

AGM

09 May 2025

10 Jul 2025

Final Dividend (₹8)

The Board Recommended a final dividend of Rs. 8/- per equity share of Rs. 1/- each for the financial year 2024-25.

09 May 2025

28 Oct 2024

Stock Split (1:5)

Face Value Change from 5 To 1

27 Jul 2024

29 Jul 2024

AGM

07 May 2024

17 Jul 2024

Final Dividend (₹40)

Recommended a final dividend of Rs. 40/- (800%) per equity share of Rs. 5/- each for the financial year 2023-24. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the ensuing 40th Annual General Meeting (AGM) of the Company.

07 May 2024

27 Jul 2023

AGM

10 May 2023

12 Jul 2023

Final Dividend (₹40)

Outcome of Board Meeting held on May 10, 2023 - Audited Financial Results and recommendation of Dividend for FY23 Recommended a final dividend of Rs. 40/- (800%) per equity share of Rs. 5/- each for the financial year 2022-23. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 39th Annual General Meeting (AGM). 39th Annual General Meeting (AGM) of the members of the Company scheduled to be held on Thursday, July 27, 2023. The Register of Members and the Share Transfer Books of the Company shall remain closed from Wednesday, July 12, 2023, to Friday, July 14, 2023 (both days inclusive) for the purpose of the Dividend and Annual General Meeting of the Company.

10 May 2023

29 Jul 2022

AGM

20 May 2022

13 Jul 2022

Final Dividend (₹30)

Dr Reddys Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 19, 2022, inter alia, has recommended a final dividend of Rs. 30/- (600%) per equity share of Rs. 5/- each for the financial year 2021-22. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 38th Annual General Meeting (AGM).

19 May 2022

28 Jul 2021

AGM

19 May 2021

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
1,244	1,03,789	18	3	14	0	17.54%
1,760	4,22,211	37	5	30	0	20.88%
6,475	1,71,898	69	11	59	0	23.41%
3,793	1,28,372	59	15	43	1	16.60%
1,515	1,22,349	22	4	19	0	19.21%
2,047	93,506	22	5	17	0	14.56%
928	93,404	19	4	15	0	19.86%
2,224	91,800	53	6	35	0	14.39%
1,240	72,630	21	2	14	0	10.98%
5,711	68,288	29	5	25	0	17.09%

Showing 10 of 124 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in less than 10 mins*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

Frequently Asked Questions

What is Share Price of Dr Reddys Laboratories Ltd?

The current share price of Dr Reddys Laboratories Ltd (Dr Reddy's Labs) is ₹1244.40. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Dr Reddys Laboratories Ltd?

The Price-to-Earnings (P/E) ratio of Dr Reddys Laboratories Ltd is 1244.40. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Dr Reddys Laboratories Ltd?

Dr Reddys Laboratories Ltd has a 52-week high of ₹1405.90 and a 52-week low of ₹1020.00. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Dr Reddys Laboratories Ltd?

Dr Reddys Laboratories Ltd offers a dividend yield of 0.64%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Dr Reddys Laboratories Ltd?

The Earnings Per Share (EPS) of Dr Reddys Laboratories Ltd is ₹69.16. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Dr Reddys Laboratories Ltd?

Dr Reddys Laboratories Ltd has a Return on Equity (ROE) of 20.15%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds.